Article citationsMore>>

Aiello, L.P., Brucker, A.J., Chang, S., Cunningham Jr, E.T., D’Amico, D.J., Flynn Jr., H.W., Grillote, L.R., Hutcherson, S., Liebmann, J.M., O’Brien, T.P., Scout, I.U., Spaide, R.F., Ta, C. and Trese, M.T. (2004) Evolving guidelines for intravitreous injections. Retina, 24, S3-S19.
http://dx.doi.org/10.1097/00006982-200410001-00002

has been cited by the following article:

• TITLE: Dobesilate for dry age-related macular degeneration

  AUTHORS: Pedro Cuevas, Luis A. Outeiriño, Carlos Azanza, Javier Angulo, Guillermo Giménez-Gallego

  KEYWORDS: Dry Age-Related Macular Degeneration; Fibroblast Growth Factor Inhibition; Intravitreal Dobesilate

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.6 No.10B, October 15, 2013

  ABSTRACT: We have evaluated the effects of intravitreal dobesilate, a synthetic fibroblast growth factor inhibitor, in patients with dry age-related macular degeneration, an inflammatory-related retinal disease without available treatment up to date. 36 eyes from 36 patients with dry age-related macular degeneration were treated with a single intravitreal dobesilate injection. The end points were the improvement from baseline visual acuity and normalization of retinal histology at one month. Intravitreal dobesilate injection resulted in a significant improvement in functional and anatomical outcomes at one month after injection. Our results suggest that intravitreal dobesilate may increase the chance of visual acuity gain in dry age-related macular degeneration, even in cases with initial low vision. This study supports the findings of previously published case reports, regarding the short-term improvement in visual acuity by intravitreal dobesilate injection in different degenerative retinal diseases.